» Articles » PMID: 36635403

[B3 Lesions of the Breast: Histological, Clinical, and Epidemiological Aspects : Update]

Overview
Specialty Pathology
Date 2023 Jan 12
PMID 36635403
Authors
Affiliations
Soon will be listed here.
Abstract

B3 lesions of the breast are a heterogeneous group of lesions with uncertain malignant potential encompassing a broad spectrum of histologically distinct alterations that often pose challenging decisions if diagnosed on the preoperative core or vacuum biopsies. B3 lesions are mostly detected due to mammographic calcifications or mass lesions and, in most cases, encompass a spectrum of atypical lesions such as atypical ductal hyperplasia, classic lobular neoplasia, flat epithelial atypia, papillomas, fibroepithelial tumors, and rarely other lesions such as mucocele-like lesions, atypical apocrine lesions, and rare stromal proliferations. The use of immunohistochemical stains (estrogen receptors, basal cytokeratin, myoepithelial markers, and stromal marker panel) is useful in the differentiation of these lesions and allowing proper classification. Regarding clinical management of B3 lesions, the radiological-pathological correlation of the given entity plays the most important key element for the proper next diagnostic and therapeutic step.

Citing Articles

Malignant upgrade in lesions of uncertain malignant potential in the breast (B3 lesions) - is open excision always necessary?.

Heindl F, Schiel J, Hack C, Amann N, Jud S, Preuss C Breast Cancer Res Treat. 2025; .

PMID: 39960605 DOI: 10.1007/s10549-025-07632-7.


Retrospective analysis of core-needle and vacuum-assisted breast biopsies of B3 fibroepithelial lesions and correlation with results in subsequent surgical specimens.

Nather S, Elfgen C, Rodewald A, Fansa H, Frauchiger-Heuer H, Varga Z J Cancer Res Clin Oncol. 2024; 150(9):436.

PMID: 39340595 PMC: 11438729. DOI: 10.1007/s00432-024-05934-9.


Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2024.

Park-Simon T, Muller V, Albert U, Banys Paluchowski M, Bauerfeind I, Blohmer J Breast Care (Basel). 2024; 19(3):165-182.

PMID: 38894952 PMC: 11182637. DOI: 10.1159/000538596.


Molecular pathology in breast disease: diagnostic, prognostic, and therapeutic tools.

Varga Z, Maccio U Virchows Arch. 2023; 484(2):247-261.

PMID: 38015260 PMC: 10948467. DOI: 10.1007/s00428-023-03709-0.

References
1.
Katayama A, Toss M, Parkin M, Ellis I, Quinn C, Rakha E . Atypia in breast pathology: what pathologists need to know. Pathology. 2021; 54(1):20-31. DOI: 10.1016/j.pathol.2021.09.008. View

2.
Ferre R, Kuzmiak C . Upgrade rate of percutaneously diagnosed pure flat epithelial atypia: systematic review and meta-analysis of 1,924 lesions. J Osteopath Med. 2022; 122(5):253-262. DOI: 10.1515/jom-2021-0206. View

3.
MacColl C, Salehi A, Parpia S, Hodgson N, Ramonas M, Williams P . Benign breast papillary lesions diagnosed on core biopsy: upgrade rate and risk factors associated with malignancy on surgical excision. Virchows Arch. 2019; 475(6):701-707. DOI: 10.1007/s00428-019-02626-5. View

4.
Elfgen C, Tausch C, Rodewald A, Guth U, Rageth C, Bjelic-Radisic V . Factors Indicating Surgical Excision in Classical Type of Lobular Neoplasia of the Breast. Breast Care (Basel). 2022; 17(2):121-128. PMC: 9149506. DOI: 10.1159/000516609. View

5.
Kilgore L, Yi M, Bevers T, Coyne R, Marita L, Lane D . Risk of Breast Cancer in Selected Women With Atypical Ductal Hyperplasia Who do not Undergo Surgical Excision. Ann Surg. 2021; 276(6):e932-e936. DOI: 10.1097/SLA.0000000000004849. View